Brainsway Ltd
BRSYF
Get informed when a big investor buys or sells
+ FollowMarket Cap$505.65M
Close$
$1.84
85.4% downside
Current Fair Value
85.4% downsideOvervalued by 85.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $505.65 Million |
|---|---|
| Enterprise Value | $460.62 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.22 |
| Beta | 0.15 |
| Outstanding Shares | 40,129,410 |
Return
| Return on Equity | 12.76% |
|---|---|
| Return on Assets | 8.28% |
| Return on Invested Capital | 5.09% |
Valuation & Multiples
| P/E Ratio | 52.61 |
|---|---|
| PEG | 159.76 |
| Price to Sales | 12.6 |
| Price to Book Ratio | 6.3 |
| Enterprise Value to Revenue | 7.1 |
| Enterprise Value to EBIT | 91.12 |
| Enterprise Value to Net Income | 45 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$16.54 M
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$17.79 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Brainsway Ltd.
CEO: Christopher von Jako Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the tr...